Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported. Here, we report a rare case of myositis after inje...

Full description

Bibliographic Details
Main Authors: Eli Magen, Sumit Mukherjee, Mahua Bhattacharya, Rajesh Detroja, Eugene Merzon, Idan Blum, Alejandro Livoff, Mark Shlapobersky, Gideon Baum, Ran Talisman, Evgenia Cherniavsky, Amir Dori, Milana Frenkel-Morgenstern
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Vaccines
Subjects:
BNT162b2
mRNA vaccine
COVID-19
myositis
Online Access:https://www.mdpi.com/2076-393X/10/7/1135

Internet

https://www.mdpi.com/2076-393X/10/7/1135

Similar Items